Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
18.09
+0.07 (0.39%)
At close: Dec 5, 2025, 4:00 PM EST
18.45
+0.36 (1.99%)
After-hours: Dec 5, 2025, 7:58 PM EST
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 26.5, with a low estimate of 15 and a high estimate of 35. The average target predicts an increase of 46.49% from the current stock price of 18.09.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 5 | 6 |
| Buy | 8 | 7 | 7 | 7 | 7 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 16 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $23 → $30 | Strong Buy | Initiates | $23 → $30 | +65.84% | Nov 24, 2025 |
| Needham | Needham | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +43.73% | Nov 4, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +49.25% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $33 → $28 | Strong Buy | Maintains | $33 → $28 | +54.78% | Oct 27, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +16.09% | Oct 23, 2025 |
Financial Forecast
Revenue This Year
86.39M
from 54.55M
Increased by 58.38%
Revenue Next Year
56.97M
from 86.39M
Decreased by -34.06%
EPS This Year
-3.21
from -2.88
EPS Next Year
-3.38
from -3.21
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 114.2M | 99.8M | ||||
| Avg | 86.4M | 57.0M | ||||
| Low | 69.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 109.4% | 15.5% | ||||
| Avg | 58.4% | -34.1% | ||||
| Low | 26.5% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.09 | -2.24 | ||||
| Avg | -3.21 | -3.38 | ||||
| Low | -3.32 | -4.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.